Lysodren Shortage: What Providers and Prescribers Need to Know in 2026

For oncologists and endocrinologists who manage patients with adrenocortical carcinoma (ACC), Lysodren (mitotane) is not merely a first-line drug — it is the only FDA-approved agent for this disease. When access to Lysodren breaks down, patients face serious clinical consequences. This guide is designed for prescribers who need to understand the current distribution landscape, proactively prevent access failures, and support their patients through the specialty pharmacy system.

Current Lysodren Availability Status (2026)

Lysodren is not listed on the FDA Drug Shortage Database as of 2026. However, clinicians managing ACC patients know that the access challenges are real. The drug's limited patient population (estimated 300–500 new U.S. cases of ACC per year), specialty-only distribution model, and high cost create a fragile supply chain where individual patient access can fail even when supply at the manufacturer level is stable.

Prescribers — particularly those in community oncology settings — may encounter Lysodren for the first time when diagnosing ACC. Familiarity with the distribution system is essential to preventing avoidable treatment delays.

Understanding the Lysodren Distribution System

Lysodren is manufactured by ESTEVE Pharmaceuticals S.A. and distributed exclusively in the United States through Direct Success Inc. (1-844-597-6373). This is the sole authorized distributor. Lysodren is not available through McKesson, AmerisourceBergen, Cardinal Health, or other pharmaceutical wholesalers used by retail pharmacies.

From the prescriber's perspective, the key points are:

Prescriptions must be routed to a specialty pharmacy within the Direct Success network — not to a retail chain

Hospital and institutional orders should also be placed through Direct Success Inc. (email: Distribution@DSuccess.com)

Prior authorization must be obtained from the patient's insurer before dispensing can occur in most cases

Financial assistance is available for qualified patients — do not assume a patient cannot afford treatment before exploring options

Prior Authorization: What to Expect and How to Reduce Delays

Most commercial insurers require prior authorization for Lysodren. Because mitotane is the only FDA-approved drug for ACC, medical necessity is generally well supported — but prior auth is still a time-consuming administrative process. To minimize delays:

Submit the prior auth on the same day as the prescription. Do not wait for the pharmacy to initiate the PA process — this delays dispensing by an average of 3–7 days.

Include a letter of medical necessity that clearly states the ACC diagnosis (ICD-10: C74.0x for malignant neoplasm of cortex of adrenal gland), the inoperable status of the disease, and the absence of FDA-approved alternatives.

Request expedited review if the patient's clinical situation is urgent. Insurance companies are legally required to process expedited requests within 72 hours.

Enlist the Direct Success team to assist with PA — they are experienced in navigating insurer requirements for Lysodren specifically.

Financial Barriers and Patient Assistance Programs

Lysodren is extremely expensive, with no generic available. Retail pricing for 100 tablets (500 mg) exceeds $3,800. At typical therapeutic doses of 6–12 tablets per day, monthly treatment costs can exceed $7,000–$14,000 out of pocket.

Financial assistance options for your patients:

Manufacturer copay support (commercial insurance): Patients with commercial insurance typically pay no more than $80/month. Enroll through Direct Success Inc. at 1-844-597-6373.

Patient Assistance Program (uninsured/underinsured): Direct Success also manages a patient assistance program for uninsured or underinsured patients who cannot afford their copay.

PAN Foundation: The Patient Access Network Foundation offers disease-specific grants. For ACC patients, PAN may provide financial assistance covering out-of-pocket treatment costs.

Medicare Part D: Lysodren is a Tier 5 specialty drug under most Medicare Part D plans. With the 2025 Medicare Part D out-of-pocket cap of $2,000, most Medicare patients with Part D coverage will reach catastrophic coverage mid-year and have reduced cost sharing for the remainder.

Clinical Management During Access Delays

If a patient cannot access Lysodren for a period of time, consider the following:

Leverage Lysodren's long half-life: Mitotane's half-life ranges from 18 to 159 days, and the drug accumulates extensively in adipose tissue. In patients who have achieved therapeutic plasma levels, a brief access gap may not immediately compromise treatment — but this should not be assumed without monitoring.

Bridging with steroidogenesis inhibitors: Ketoconazole, metyrapone, or osilodrostat can maintain cortisol control in functional ACC patients during a Lysodren gap. These agents do not replace mitotane's cytotoxic or adrenolytic effects but can prevent life-threatening hypercortisolism.

Steroid replacement vigilance: All patients on mitotane should be on adrenal replacement therapy. During access gaps, ensure steroid replacement continues uninterrupted and that patients have emergency hydrocortisone kits for adrenal crisis.

Pre-Initiation Checklist for Lysodren Prescribers

Before starting a patient on Lysodren, confirm the following:

Pelvic ultrasound performed in premenopausal women (per prescribing information)

Liver function tests (LFTs) and complete blood count (CBC) obtained

Contraception counseling completed for all women of reproductive potential (hormonal contraceptives will not be reliable)

Steroid replacement therapy initiated or planned

Drug interaction review completed — particularly for warfarin, spironolactone, and CYP3A4 substrates

Specialty pharmacy enrollment initiated through Direct Success Inc.

Prior authorization submitted and patient financial assistance secured

How medfinder Supports Your Patients

When your patients report difficulty filling their Lysodren prescription, medfinder can help. medfinder is a paid service that calls pharmacies in the patient's area to check which ones can fill a specific prescription, then texts the results to the patient. For rare specialty drugs, this kind of targeted search is far more efficient than patients calling pharmacies one by one. Learn more at medfinder.com/providers.

For more on helping patients find Lysodren, see: How to Help Your Patients Find Lysodren In Stock: A Provider's Guide.